Confo Therapeutics’ technology stabilizes functional conformations of G protein-coupled receptors to uncover a wide range of previously inaccessible drug targets
Confo Therapeutics, a spin-off of the Vrije Universiteit Brussel and VIB, is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
AmphiStar offers a portfolio of locally sourced biosurfactants to companies seeking to develop sustainable, performant & affordable products
Trince developed a new transfection technology based on a combination of laser light and photothermal nanoparticles
QustomDot is developing cadmium-free quantum dots that are stable enough for advanced applications
